post-marketing requirement
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months
FDA; Ascendis Pharma; TransCon CNP; navepegritide; achondroplasia; dwarfism; PDUFA; post-marketing requirement; delay; approval
Actionable Insights Powered by AI
FDA; Ascendis Pharma; TransCon CNP; navepegritide; achondroplasia; dwarfism; PDUFA; post-marketing requirement; delay; approval